Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL746604 | 0.83 | CYP11B1 (0.51) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3664657 | 0.83 | CYP11B1 (0.48) | CYP11B1CYP11B2IDO1EGFRMAPT | |
| SCHEMBL1532963 | 0.82 | HSP90AB1 (0.47) | CYP11B1CYP11B2KDM4ESMN1; SMN2HPGD | |
| Hydrochloric Acid SCHEMBL17396793 | 0.82 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3931688 | 0.81 | CYP11B1 (0.48) | CYP11B1CYP11B2KDM4EMAPTHTT | |
| SCHEMBL22186888 | 0.81 | HDAC1 (0.42) | CYP11B1CYP11B2KDM4EMAPTHTT | |
| SCHEMBL21476653 | 0.81 | CYP11B1 (0.41) | CYP11B1CYP11B2KDM4EMAPTHTT | |
| SCHEMBL30701976 | 0.81 | HDAC1 (0.42) | CYP11B1CYP11B2KDM4EMAPTHTT | |
| SCHEMBL1475664 | 0.80 | POLB (0.48) | KDM4EMAPTHTTSMN1; SMN2POLB | |
| SCHEMBL21475991 | 0.78 | CYP11B1 (0.39) | CYP11B1CYP11B2KDM4EMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4565574-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20230138901-A1 | COMPOUND HAVING KHK INHIBITORY EFFECT | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230138901-A1 | COMPOUND HAVING KHK INHIBITORY EFFECT | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2021129737-A1 | COMPOUND HAVING KHK INHIBITORY EFFECT | 南京明德新药研发有限公司 | 2021-07-01 | — | — | WO | disclosed |
| US-8383827-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-8383827-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| EP-2429995-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130796-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | disclosed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | disclosed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | disclosed |
| WO-2003027101-A1 | SUBSTITUTED 3-PYRIDYL PYRROLES AND 3-PYRIDYL PYRAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | CYP11B1 3367/4885CYP11B2 1461/4885CYP1A2 152/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | CYP11B1 3367/4885CYP11B2 1461/4885CYP1A2 152/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | CYP11B1 3367/4885CYP11B2 1461/4885CYP1A2 152/4885 |
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP11B1 2/4885CYP11B2 4/4885CYP1A2 16/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | CYP11B1 3367/4885CYP11B2 1461/4885CYP1A2 152/4885 |
| US-20230138901-A1 | COMPOUND HAVING KHK INHIBITORY EFFECT | KHK, KHDRBS1, KHSRP | CYP11B1 626/4885CYP11B2 614/4885CYP1A2 4018/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | CYP11B1 3367/4885CYP11B2 1461/4885CYP1A2 152/4885 |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP11B1 2/4885CYP11B2 4/4885CYP1A2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.